MedTrace Logo

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

NCT02559024 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2022-02-14

No results posted yet for this study

Summary

This study will test the ability of an immune modulator, anti-OX40 (MEDI6469) to alter the immune cell environment within colorectal cancer metastases. The drug will be administered to patients before surgical treatment.

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

MEDI6469

MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days

Sponsors & Collaborators

  • MedImmune LLC

    collaborator INDUSTRY

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Pippa Newell, MD · Providence Health & Services

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-14
Primary Completion
2018-10-31
Completion
2018-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02559024 on ClinicalTrials.gov